News Search Results
Oct 09, 2025, 17:14 ET Alamar Biosciences Launches NULISAqpcr™ BD-pTau217 Assay: A Breakthrough in Non-Invasive, Brain-Specific Biomarker Detection for Alzheimer's Disease Research
measurement of CNS-derived pTau217 without the need for cerebrospinal fluid (CSF) collection or PET imaging removes existing barriers to widespread adoption in population-based studies or longitudinal clinical trials. "The NULISAqpcr BD-pTau217 Assay redefines what's possible in CNS biomarker
More news about: Alamar Biosciences, Inc.
Oct 09, 2025, 16:54 ET Alamar Biosciences Launches NULISAqpcr™ BD-pTau217 Assay: A Breakthrough in Non-Invasive, Brain-Specific Biomarker Detection for Alzheimer's Disease Research
measurement of CNS-derived pTau217 without the need for cerebrospinal fluid (CSF) collection or PET imaging removes existing barriers to widespread adoption in population-based studies or longitudinal clinical trials. "The NULISAqpcr BD-pTau217 Assay redefines what's possible in CNS biomarker
More news about: Alamar Biosciences, Inc.
Oct 09, 2025, 09:30 ET Monteris Medical and Symphony Robotics Announce Strategic Collaboration to Launch AI-Driven Micro-Robotic Platform for Laser Ablation in the Brain
major professional medical organizations including the American Association of Neurological Surgeons (AANS), the Congress of Neurological Surgeons (CNS), the American Association for Stereotactic and Functional Neurosurgery (ASSFN) and the National Comprehensive Cancer Network® (NCCN), Monteris has led
More news about: Monteris Medical
Oct 09, 2025, 07:52 ET Cadenza Bio Announces Peer-Reviewed Study Showing Oral, Brain-Penetrant ERβ Ligands Drive Remyelination and Functional Recovery in MS Models
Dosing: K102 and K110 achieved biologically relevant brain concentrations across species following oral administration, supporting their potential for CNS activity. "These findings highlight a novel dual mechanism of action supported by functional endpoints
More news about: Cadenza Bio, Inc.
Oct 09, 2025, 03:00 ET ARTHEx Biotech to Participate in Upcoming Investor and Industry Events
I/IIa ArthemiR™ trial. Building on this foundation, ARTHEx is advancing a pipeline of therapies for additional areas of high unmet need across muscular, CNS, and cardiac diseases. The Company headquarters are in Valencia, Spain. For more information on ArthemiR™,
More news about: ARTHEx Biotech
Oct 08, 2025, 21:00 ET 코헨 앤드 스티어스, DBS 뱅크와 손잡고 코헨 앤드 스티어스 다각화 실물 자산 펀드에 접근할 수 있는 기회 제공
https://www.cohenandsteers.com기호: NYSE: CNS
More news about: Cohen & Steers, Inc.
Oct 08, 2025, 19:05 ET EMA Wellness Bolsters Executive Leadership to Scale its Market Leading Clinical Trial Platform
the heels of EMAW's continued global ascension as the new market standard in eCOA, digital data collection and integration and clinical analysis in CNS clinical trials. EMAW's web-based technology and singular code base drive the feature functionality of its proprietary GIANT™ platform. GIANT™ unifies
More news about: EMA Wellness
Oct 08, 2025, 16:42 ET Cohen & Steers, Inc. to Release Third Quarter 2025 Results on October 16, 2025
NEW YORK, Oct. 8, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced that it expects to release third quarter 2025 results after the market closes on Thursday, October 16, 2025. The earnings release and accompanying
More news about: Cohen & Steers, Inc.
Oct 08, 2025, 16:28 ET Cohen & Steers Announces Preliminary Assets Under Management and Net Flows for September 2025
NEW YORK, Oct. 8, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $90.9 billion as of September 30, 2025, an increase of $542 million from assets under management
More news about: Cohen & Steers, Inc.
Oct 08, 2025, 14:48 ET Theranica Brings First-in-Class, Drug-Free Migraine Care to the Forefront at CNS 2025 with Product Theater and New Real-World Evidence
2025 Child Neurology Society (CNS) Annual Meeting, held in Charlotte, N.C. The company will present two new real-world evidence (RWE) posters and host a dedicated product theater
More news about: Theranica
Oct 08, 2025, 14:03 ET Phantom Neuro CEO Connor Glass to Present during BioFuture™ 2025
, CEO and founder Phantom Neuro, will present during a Spotlight Panel, " Rewiring Minds: Breakthroughs in Brain & CNS Health" (Spotlight Panel 1B). More information: This panel will be held on Monday, October
More news about: Phantom Neuro Inc.
Oct 08, 2025, 09:00 ET Neurelis to Highlight Data from a Study of Diazepam Nasal Spray in Pediatric Patients at the Child Neurology Society Annual Meeting
narrow-angle glaucoma Central Nervous System (CNS) DepressionBenzodiazepines, including VALTOCO, may produce CNS depression. Caution patients against engaging in hazardous activities requiring mental alertness, such as operating
More news about: Neurelis, Inc.
Oct 07, 2025, 09:00 ET Precision NeuroMed Granted FDA Orphan Drug Designation by U.S. FDA for Treatment of Glioblastoma Multiforme (GBM)
PNM), a clinical-stage biotechnology company pioneering advanced drug delivery technologies for central nervous system (CNS) diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its investigational therapy for glioblastoma
More news about: Precision NeuroMed
Oct 07, 2025, 08:30 ET Boosting clinical trial success in Alzheimer's, Parkinson's and other neurodegenerative diseases, Upcoming Webinar Hosted by Xtalks
efficiency of clinical trials for neurodegenerative diseases. The featured speakers will discuss strategies for integrating biomarkers into early-phase CNS clinical trials to improve patient diagnosis and treatment evaluation. The speakers will also discuss best practices to improve the success rates in
More news about: Xtalks
Oct 07, 2025, 08:00 ET GEMMABio Launches Rare Therapeutics, Inc. to Develop and Deliver Gene Therapies for Ultra‑Orphan Diseases
RareTx's portfolio is based on therapeutic platforms directed to monogenic disease that affect the central nervous system (CNS) or heart/skeletal muscle. The lead clinical-stage CNS programs include GM1 gangliosidosis ("GM1"), Krabbe disease ("Krabbe") and metachromatic leukodystrophy ("MLD"), ultra-orphan
More news about: GEMMA Biotherapeutics
Oct 07, 2025, 07:00 ET Peer AI Raises $12.1 Million to Accelerate Drug Approvals with an Intelligent Regulatory Workflow
CNS Summit to learn more and see a solution demo. About Peer AIPeer AI transforms regulatory
More news about: Peer AI
Oct 06, 2025, 08:30 ET Neuropsychiatry Clinical Trials: Evolving with Portable EEG and Digital Endpoints, Upcoming Webinar Hosted by Xtalks
In this free webinar, hear from CNS thought-leaders on the transformative power of objective measures of brain function in neuropsychiatry clinical trials. Attendees will gain insight into the power of EEG data synchronized with behavioural assessment data for
More news about: Xtalks
Oct 03, 2025, 22:48 ET Clearmind Biomedical Signs Exclusive U.S. Distribution Agreement with Sutter Medical Technologies USA and launches the Neuroblade System at Congress of Neurological Surgeons (CNS) Los Angeles, CA.
workflow, precision and enhance patient outcomes." The Neuroblade will be featured at the Congress of Neurological Surgeons (CNS) Annual Meeting, October 11-15th, 2025 at Booth #350. About Clearmind Biomedical
More news about: Clearmind Biomedical Inc.
Oct 03, 2025, 09:00 ET Mitsubishi Tanabe Pharma America to Present New Data on Investigational ND0612 at the 2025 International Congress of Parkinson's Disease and Movement Disorders®
therapies and technologies. NeuroDerm is an integrated pharmaceutical and medical technology company developing central nervous system (CNS) product candidates. For additional information, please visit NeuroDerm's website at
More news about: Mitsubishi Tanabe Pharma America
Oct 03, 2025, 08:30 ET Koh Young to Showcase Next Gen Navigated Neurosurgical Robot at CNS Innovation Symposium
announced it will present its FDA-cleared navigated neurosurgical positioning robot, Geniant® Cranial at the upcoming Congress of Neurological Surgeons (CNS) "Special Symposium: Transforming Neurosurgery through Technology," taking place on October 12, 2025.
More news about: Koh Young Technology
Oct 02, 2025, 11:36 ET ExQor Technologies Announces Advancement Toward Clinical Trials for Brain Regenerative Medicine Platform to Treat Alzheimer's Disease
platform offers exceptional flexibility, paving the way for large molecule therapies—including those previously unable to reach therapeutic levels in the CNS—to become viable options for treatment of neurological conditions, brain cancers, and gene therapies. Market
More news about: ExQor Technologies Inc
Oct 02, 2025, 08:08 ET Eisai Highlights Breadth of Oncology Research at ESMO 2025, Featuring 5-Year Survival Data from Study 309/KEYNOTE-775
3-5 hemorrhage occurred in 2% of LENVIMA-treated patients, including 1 fatal intracranial hemorrhage among 16 patients who received LENVIMA and had CNS metastases at baseline. In RCC, grade 3-5 hemorrhage occurred in 8% of LENVIMA + everolimus–treated patients, including 1 fatal cerebral hemorrhage.
More news about: Eisai Inc.
Oct 02, 2025, 08:00 ET Aminex Therapeutics Announces FDA Orphan Drug Designation Granted to AMXT 1501 in Combination with DFMO for the Treatment of Neuroblastoma
Escalation Study Using Eflornithine (DFMO) and AMXT 1501 Followed by a Randomized Controlled Trial of DFMO with or without AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas"
More news about: Aminex Therapeutics, Inc.
Oct 02, 2025, 06:36 ET ExQor Technologies Announces Advancement Toward Clinical Trials for Brain Regenerative Medicine Platform to Treat Alzheimer's Disease
platform offers exceptional flexibility, paving the way for large molecule therapies—including those previously unable to reach therapeutic levels in the CNS—to become viable options for treatment of neurological conditions, brain cancers, and gene therapies. Market
More news about: ExQor Technologies Inc
Oct 01, 2025, 10:00 ET Surgical Theater Surpasses 50,000 XR Utilizations
The announcement comes as Surgical Theater prepares to showcase new capabilities at CNS and NASS congresses this fall, where surgeons and hospital leaders will experience firsthand how XR transforms planning and intraoperative execution.
More news about: SURGICAL THEATER